ONCODNA

Company Overview

Founded in 2012, OncoDNA is developing and marketing diagnostics for oncology applications based on a range of technologies, including sequencing and immunohistochemistry. The objective of these tests is to generate a patient profile that can be used to assess response to chemotherapies. The company’s geographic focus is Europe. OncoDNA has a subsidiary in Spain, BioSequence, which serves markets in Spain, Portugal and Latin America.

The strategic objective of OncoDNA is to offer services that can systematically sequence a patient’s tumor genome, thus allowing for personalized cancer treatment. OncoDNA is developing a proprietary database of mutations and their links to marketed drugs and clinical trials. Marketed products include OncoDeep, OncoStrat&Go, OncoTrace, OncoShare, and OncoKDM.

OncoDEEP uses a tiered approach to detecting tumor mutations that can respond to cancer therapies. The initial test is linked to all the targeted anticancer drugs currently on the European market. If no mutations of interest are detected, the second-tier test is used, which links to all genes associated with newly developed drugs in clinical trials. Finally, a third-tier test looks at all genes to see if actionable mutations can be linked to other types of drugs.

OncoDeep is used for solid tumors and combines NGS with IHC, FISH, methylation analysis, and translocation analysis.

OncoTrace is a liquid biopsy assay that is used to monitor the cancer during treatment. The assay analyzes a panel of 411 genes that are associated with resistance or sensitivity to therapies.

OncoStrat&Go combines the analysis of a solid biopsy and a liquid biopsy in a single assay. The assay examines 28 genes. OncoShare and OncoKDM are software tools for sharing information and interpreting data.

In July 2020, OncoDNA acquired IntegraGen, a bioinformatics company based in France. This acquisition enables OncoDNA to integrate IntegraGen’s software into its own clinical workflow to offer a premium service for cancer analytics and it also increased OncoDNA’s presence in the European biopharma industry.

In January 2021, OncoDNA formed an alliance with HalioDx to expand its pharma testing services into North America. HalioDx is an immune-oncology company that operates a CLIA-certified laboratory in the state of Virginia. HalioDx agreed to perform OncoDNA’s molecular profiling assays for pharma customers in the United States.

OncoDNA’s NGS-based tests are used in several pharmaceutical clinical trials. These include an alliance with Kura Oncology to test to identify head and neck cancer patients with HRAS mutations who could be eligible for Kura’s drug tipifarnib; and testing under the AURORA study, being led by the Breast International Group, to gain insights into genetic markers associated with metastatic breast cancer and molecular mechanisms that may drive therapy response and resistance.

In November 2022, OncoDNA and Eli Lilly Italia, a healthcare company specializing in life-changing medicines, announced a partnership to facilitate access to biomarker testing and support the selection of optimal therapy for thyroid cancer patients in Italy.

Company's Business Segments

• Precision Medicine : OncoDNA improve patients’ outcomes by empowering Physicians, Biopharma Companies, Researchers to deliver the promise of precision medicine.